Pharmaceuticals, Biotechnology & Life Sciences

Insider sales at Codexis amid volatile pricing show how RSU vesting can signal valuation concerns—evaluate the dip for long‑term value potential.

Winklevoss Capital boosts its stake in CYPHERPUNK Technologies, adding 5 M shares via warrant conversion—strengthening voting power amid a volatile, low‑price stock and high social‑media buzz. Click to learn the strategic implications for investors …

CEO Martine Rothblatt’s 10 b5‑1 trade shows disciplined liquidity management, boosting confidence in United Therapeutics’ solid biotech growth.

Danaher insider sale by Mitchell Rales signals strategic confidence: board expansion, high‑growth focus, and strong drug‑pipeline positioning.

Investors eye MEDPACE after Susan Burwig’s insider buy—analyzing the company’s rapid clinical pipeline, FDA fast‑track approvals, and steady share gains.

Nurix insider buys: Gregory Julia P. adds 22,583 shares at $23.67 as the stock rebounds from a 52‑week low, signaling renewed confidence in its biopharma pipeline and Roche partnership.

Summit Therapeutics CFO’s 100k share purchase shows long‑term confidence amid volatility—insider buy hints at future upside tied to clinical milestones.

Mirum Pharma’s insider buying signals confidence ahead of LIVMARLI’s sNDA, suggesting a potential valuation lift despite regulatory risks.

CEO Jennifer Buell’s fresh 23k‑share buy shows strong confidence in MINK Therapeutics’ iNKT cell therapy pipeline amid a tough biotech market, signaling potential upside for investors.

Insightful insider selling at ANI Pharmaceuticals: Cook Meredith’s Rule 10b5‑1 trades reveal steady outflows, hinting at management’s liquidity strategy without signalling immediate weakness.